Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Issue 1
Clinical Pharmacology: Advances and Applications
ISSN: 1179-1438
- View all (264)
- Volume 15, 2023 (9)
- Volume 14, 2022 (12)
- Volume 13, 2021 (27)
- Volume 12, 2020 (28)
- Volume 11, 2019 (16)
- Volume 10, 2018 (19)
- Volume 9, 2017 (19)
- Volume 8, 2016 (20)
- Volume 7, 2015 (14)
- Volume 6, 2014 (23)
- Volume 5, 2013 (30)
- Volume 4, 2012 (11)
- Volume 3, 2011 (7)
- Volume 2, 2010 (28)
- Volume 1, 2009 (1)
Archive: Volume 5, 2013
- Issue 1 (23)
- Supplement 1 (7)

Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum
Decker BS, O’Neill KD, Chambers MA, Slaven JE, Yu Z, Jones DR, Moe SM
Clinical Pharmacology: Advances and Applications 2013, 5:193-199
Published Date: 10 December 2013

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang CW, Kovacs RJ, Flockhart DA
Clinical Pharmacology: Advances and Applications 2013, 5:185-192
Published Date: 9 December 2013

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Clinical Pharmacology: Advances and Applications 2013, 5:177-184
Published Date: 6 December 2013

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Lozano R, Domeque N, Apesteguia AF
Clinical Pharmacology: Advances and Applications 2013, 5:175-176
Published Date: 22 November 2013

Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes
Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G
Clinical Pharmacology: Advances and Applications 2013, 5:167-174
Published Date: 19 November 2013

High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
Yabuno K, Seki M, Miyawaki K, Miwa Y, Tomono K
Clinical Pharmacology: Advances and Applications 2013, 5:161-166
Published Date: 5 November 2013

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
Lozano R, Domeque N, Apesteguia AF
Clinical Pharmacology: Advances and Applications 2013, 5:153-159
Published Date: 27 September 2013

Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation
Pickett A
Clinical Pharmacology: Advances and Applications 2013, 5:149-152
Published Date: 5 September 2013

Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban
Kwong LM
Clinical Pharmacology: Advances and Applications 2013, 5:143-148
Published Date: 2 August 2013

Single-dose fentanyl sublingual spray for breakthrough cancer pain
Taylor DR
Clinical Pharmacology: Advances and Applications 2013, 5:131-141
Published Date: 24 July 2013

Impact of denosumab on bone mass in cancer patients
Brown-Glaberman U, Stopeck AT
Clinical Pharmacology: Advances and Applications 2013, 5:117-129
Published Date: 4 July 2013

Synthetic cathinone abuse
Capriola M
Clinical Pharmacology: Advances and Applications 2013, 5:109-115
Published Date: 2 July 2013

Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review
Brennan JL, Leung JG, Gagliardi JP, Rivelli SK, Muzyk AJ
Clinical Pharmacology: Advances and Applications 2013, 5:99-107
Published Date: 3 July 2013

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP
Clinical Pharmacology: Advances and Applications 2013, 5:85-97
Published Date: 10 June 2013

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
Davis EM, Knezevich JT, Teply RM
Clinical Pharmacology: Advances and Applications 2013, 5:67-83
Published Date: 19 April 2013

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE
Clinical Pharmacology: Advances and Applications 2013, 5:59-66
Published Date: 16 April 2013

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
Bartosh NS, Tomlin T, Cable C, Halka K
Clinical Pharmacology: Advances and Applications 2013, 5:53-58
Published Date: 15 March 2013

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
Prager W
Clinical Pharmacology: Advances and Applications 2013, 5:39-52
Published Date: 12 March 2013

Effect of statin therapy on vaspin levels in type 2 diabetic patients
Al-Azzam SI, Alzoubi KH, Abu Abeeleh J, Mhaidat NM, Abu-Abeeleh M
Clinical Pharmacology: Advances and Applications 2013, 5:33-38
Published Date: 20 February 2013

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
van Rossem K, Lowe JA
Clinical Pharmacology: Advances and Applications 2013, 5:23-31
Published Date: 30 January 2013

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Nanda K, Moss AC
Clinical Pharmacology: Advances and Applications 2013, 5:21-22
Published Date: 22 January 2013

Arginine deprivation therapy for malignant melanoma
Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB
Clinical Pharmacology: Advances and Applications 2013, 5:11-19
Published Date: 27 December 2012

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
Thomas RP, Recht L, Nagpal S
Clinical Pharmacology: Advances and Applications 2013, 5:1-9
Published Date: 27 December 2012